Christophe Quéva, PhD, CEO, is a seasoned professional in the biopharmaceutical industry, currently serving as the Co-Founder, CEO, and President of Ovie Therapeutics. His role if to lead company creation, fund raising and OVI-719 overall development. He is also Chief Scientific Officer (CSO) at DEM Biopharma, Inc. where he leads the development of a portfolio of first-in-class candidate drugs directing innate immune cells in their combat against cancer.

 

Before joining DEM Biopharma, Christophe was the CSO at Oncorus, a clinical-stage biotechnology company specializing the use of oncolytic viruses to stimulate anti-tumor immunity. At Oncorus, he lead the work spanning multiple years leading to the optimization of OVI-719. Prior to Oncorus, Christophe held the position of CSO at iTeos Therapeutics from 2015 to 2017, where he was instrumental in advancing the company’s immuno-oncology portfolio. Additionally, Christophe has had significant leadership roles at Gilead Sciences, Amgen, and AstraZeneca, contributing to various oncology and immunology projects.

 

Christophe educational background includes a Ph.D. in Life and Health Sciences from the University of Lille, France, and post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle. He is an author on more than 30 scientific publication and an inventor on 15 patents and applications.